Developers recently said that the first dengue vaccine may enter the market in a clinical trial showed encouraging results in Latin America, vaccinated virus infection rate dropped 60.8 percent.
Aegypti is the main carrier of dengue fever germs. (Source: WIKIMEDIA COMMONS)
Developers recently said that the first dengue vaccine may enter the market in a clinical trial showed encouraging results in Latin America, vaccinated virus infection rate dropped 60.8 percent. This vaccine is approved for use as early as next year, then, countries affected by dengue affected will face a tough choice: whether it can provide limited protection worth the price.
By Dengue fever is a mosquito-borne disease endemic throughout tropical and subtropical regions, brought a heavy burden for health care in Asia and the Americas. In the absence of effective drugs, is expected to have an annual 20,000 of those infected with 500,000 patients require hospitalization. The initial infection of four different dengue virus serotypes in a usually mild. The second serotype infections will cause serious symptoms, including debilitating fever, joint and muscle pain and bleeding. Dengue experts believe, to delay a second infection complications, a vaccine must be provided for the four serotypes of balanced protection – which is very difficult to make vaccine research and development.
In early trials in Southeast Asia, from five countries, more than 10,000 children and young people received three vaccines. In addition to reducing the overall incidence of dengue fever, but the vaccine will be reduced by 88.5% in severe cases. But the effectiveness of the vaccine against type 2 sera of only 35%, which was the region’s most popular serotypes, thus weakening the overall effect.
Latin American trial included 20,875 participants in five countries, aged 9 to 16 years, the results showed that the vaccine reduced the hospitalization rate 80.3%, and the effectiveness of the serum against type 2 was 42.3%. Pharmaceutical giant Sanofi Pasteur scientists will announce details of vaccines in the United States Society of Tropical Medicine and Hygiene annual meeting in November.
Sanofi Pasteur has invested $ 400 million facility, capable of producing 100 million vaccines each year. The company said it will be later this year or early 2015 for approval of the vaccine market. However, some countries may not willing to believe it. Singapore Environment Minister Vivian Balakrishnan said before, based on the demonstrated vaccine trials in Southeast Asia against type 1 and type 2 serum limited, it is not enough to be added to the country’s immunization program.